Related Experiment Video

Updated: Aug 15, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

13.6K

BMPR2 gene mutation in pulmonary arteriovenous malformation and pulmonary hypertension: a case report

Tomohiro Handa1, Yoshiaki Okano2, Norifumi Nakanishi3

  • 1Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Respiratory Investigation
|May 24, 2014
PubMed

Insights

Bone morphogenetic protein receptor type 2 (BMPR2) gene mutations may be linked to pulmonary arteriovenous malformation (PAVM) and pulmonary arterial hypertension (PAH). This case highlights a potential genetic association in complex cardiovascular conditions.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Pulmonary Hypertension

Background:

  • The transforming growth factor-β superfamily signaling pathway is implicated in pulmonary arteriovenous malformation (PAVM) pathogenesis.
  • The specific role of bone morphogenetic protein receptor type 2 (BMPR2) gene mutations in PAVM is not well-established.

Observation:

  • A case of concurrent PAVM and pulmonary arterial hypertension (PAH) is presented.
  • The patient had a deletion mutation in exons 6 and 7 of the BMPR2 gene.
  • PAH treatment improved hemodynamics and exercise capacity but worsened oxygenation.

Findings:

  • The study suggests a potential association between BMPR2 gene mutations and the co-occurrence of PAVM and PAH.
  • This genetic mutation may contribute to the complex clinical presentation observed in the patient.

Implications:

  • Understanding the genetic basis of PAVM and PAH can lead to improved diagnostic and therapeutic strategies.
  • Further research into BMPR2 mutations may uncover novel therapeutic targets for these conditions.
  • This case underscores the importance of genetic testing in patients with combined PAVM and PAH.
Keywords:
AmbrisentanBone morphogenetic protein receptor type 2Pulmonary arterial hypertensionPulmonary arteriovenous malformationSildenafil

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

6.9K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

9.8K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...